Eli Lilly and Company (NYSE:LLY) Shares Sold by Parcion Private Wealth LLC

Parcion Private Wealth LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 56.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,175 shares of the company’s stock after selling 1,542 shares during the period. Parcion Private Wealth LLC’s holdings in Eli Lilly and Company were worth $1,041,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of LLY. Private Ocean LLC grew its stake in shares of Eli Lilly and Company by 8.2% in the 1st quarter. Private Ocean LLC now owns 1,092 shares of the company’s stock worth $850,000 after purchasing an additional 83 shares during the last quarter. Vicus Capital grew its stake in shares of Eli Lilly and Company by 57.4% in the 1st quarter. Vicus Capital now owns 861 shares of the company’s stock worth $670,000 after purchasing an additional 314 shares during the last quarter. Brown Miller Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $243,000. Fox Hill Wealth Management grew its stake in shares of Eli Lilly and Company by 4.9% in the 1st quarter. Fox Hill Wealth Management now owns 10,540 shares of the company’s stock worth $8,200,000 after purchasing an additional 492 shares during the last quarter. Finally, Foguth Wealth Management LLC. acquired a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $482,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on LLY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Finally, Truist Financial upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,013.41.

Eli Lilly and Company Stock Up 0.2 %

Shares of NYSE:LLY opened at $892.70 on Friday. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company’s 50-day moving average price is $919.74 and its two-hundred day moving average price is $862.48. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The firm has a market cap of $848.45 billion, a P/E ratio of 109.94, a P/E/G ratio of 3.24 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, research analysts forecast that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.